A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

DSpace/Manakin Repository

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

Citable link to this page


Title: A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Author: Johannessen, Cory M.; Johnson, Laura A.; Piccioni, Federica; Townes, Aisha; Frederick, Dennie T.; Donahue, Melanie K.; Narayan, Rajiv; Flaherty, Keith T.; Wargo, Jennifer A.; Root, David E.; Garraway, Levi A.

Note: Order does not necessarily reflect citation order of authors.

Citation: Johannessen, C. M., L. A. Johnson, F. Piccioni, A. Townes, D. T. Frederick, M. K. Donahue, R. Narayan, et al. 2014. “A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.” Nature 504 (7478): 138-142. doi:10.1038/nature12688. http://dx.doi.org/10.1038/nature12688.
Full Text & Related Files:
Abstract: BRAFV600E-mutant malignant melanomas depend on RAF/MEK/ERK (MAPK) signaling for tumor cell growth1. RAF and MEK inhibitors show remarkable clinical efficacy in BRAFV600E melanoma2, 3; however, resistance to these agents remains a formidable challenge2, 4. Global characterization of resistance mechanisms may inform the development of more effective therapeutic combinations. Here, we performed systematic gain-of-function resistance studies by expressing >15,500 genes individually in a BRAFV600E melanoma cell line treated with RAF, MEK, ERK, or combined RAF/MEK inhibitors. These studies revealed a cyclic AMP-dependent melanocytic signaling network not previously associated with drug resistance, including G-protein coupled receptors, adenyl cyclase, protein kinase A and cAMP response element binding protein (CREB). Preliminary analysis of biopsies from BRAFV600E melanoma patients revealed that phosphorylated (active) CREB was suppressed by RAF/MEK-inhibition but restored in relapsing tumors. Expression of transcription factors activated downstream of MAP kinase and cAMP pathways also conferred resistance, including c-FOS, NR4A1, NR4A2 and MITF. Combined treatment with MAP kinase pathway and histone deacetylase inhibitors suppressed MITF expression and cAMP-mediated resistance. Collectively, these data suggest that oncogenic dysregulation of a melanocyte lineage dependency can cause resistance to RAF/MEK/ERK inhibition, which may be overcome by combining signaling- and chromatin-directed therapeutics.
Published Version: doi:10.1038/nature12688
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4098832/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:12717516
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search